The contribution of transcriptional activation to the p53 effector functions critical for tumor suppression, apoptosis and cellular senescence, remains unclear because of p53's ability to regulate diverse cellular processes in a transactivation-independent manner. Dissociating the importance of transactivation from other p53 functions, including regulating transcriptional repression, DNA replication, homologous recombination, centrosome duplication, and mitochondrial function, has been difficult because of overlapping motifs for these functions in the amino terminus. To determine the relative contribution of these activities and transactivation to p53 function, we generated knockin mice expressing a p53 mutant lacking domains involved in these transactivation-independent functions, while remaining competent for transactivation through fusion to the Herpes Simplex Virus VP16 transactivation domain. This chimeric mutant, termed p53 VP16 , robustly activates the transcription of a range of p53 targets involved in both apoptosis and senescence. Intriguingly, despite being transactivation-competent, this chimeric protein shows selectivity in p53 effector function in mouse fibroblasts, with a capacity to trigger senescence but not apoptosis under a variety of conditions. Our study highlights the central role of p53 transactivation for senescence while suggesting that transactivation is insufficient for apoptosis, and provides insight into the mechanisms by which p53 serves as a tumor suppressor. mouse model ͉ transactivation ͉ tumor suppression
T
he p53 tumor suppressor gene is a frequent target of mutation in human cancer, and loss of p53 function is frequently associated with malignant progression (1). p53's tumor suppressor activity has been attributed largely to its ability to induce apoptosis, senescence, or temporary cell cycle arrest in response to various insults, including genotoxic stresses, oncogenic signaling, and hypoxia (2) . The best-characterized biochemical activity of p53 is the ability to stimulate transcription of a large cohort of target genes involved in implementing growth arrest or apoptosis (3) . To function as a transactivator, p53 binds to discrete sites in the promoters and introns of genes in a sequence-specific manner and recruits numerous proteins, including components of the basal transcriptional apparatus, histone acetyltransferases, and other transcriptional cofactors essential for transcriptional initiation (4) . Two discrete transcriptional activation domains in the p53 amino terminus, comprising residues 25 and 26 or 53 and 54, respectively, play key roles in interactions with these factors and in stimulating transcription (5, 6) .
However, despite p53's function as a transcriptional activator being the most extensively studied facet of p53 function, the contribution of transcriptional activation to p53's role as a tumor suppressor remains surprisingly elusive. Specifically, studies using transcriptional activation-compromised p53 mutants have indicated that p53 can retain activity in the absence of transactivation potential (7, 8) . Moreover, p53 has been shown to possess diverse additional activities, in regulating transcriptional repression, DNA replication and DNA recombination, centrosome duplication, and mitochondrial membrane integrity (9) (10) (11) (12) (13) (14) (15) (16) . As with the transactivation domains, important functional motifs for these discrete activities reside in the p53 amino terminus. For example, p53 can repress transcription through interactions of residues 61-75 in the proline-rich domain with mSin3a and histone deacetylases (HDACs) (12) . Additionally, p53 can regulate DNA replication and homologous recombination through interactions of residues 48-54 with Replication Protein A (13, 16) and centrosome duplication in a manner dependent on residues 13 and 17 (14) . Finally, p53 can act directly at the mitochondria to induce mitochondrial membrane permeabilization through association with members of the Bcl-2 superfamily, also through the proline-rich domain (9, 10, 15) . Thus, the amino terminus plays a central part in various p53 activities.
Here, to determine the relative roles of transactivation and other amino-terminal activities for p53 function, we generated knockin mice expressing a p53 mutant lacking domains involved in diverse transactivation-independent functions but still retaining p53 transactivation capacity. We removed the aminoterminal 80 aa of p53 implicated in transcriptional activation, transcriptional repression, centrosome duplication, mitochondrial function, and DNA replication/recombination, and replaced them with the transactivation domain of the Herpes Simplex Virus VP16 protein, a well characterized activation domain that can confer transactivation potential on heterologous DNA binding domains. This strategy should generate a transcriptionally active protein with the target gene specificity of p53 due to the presence of the endogenous DNA binding domain, but deficient for various other amino-terminal p53 functions. Analysis of this mutant, coupled with the knockin mouse strategy to enable analysis of primary cells with p53 expression driven by its own promoter at endogenous levels, provides an effective approach for clearly defining the requirements for p53 function in its effector pathways important for tumor suppression, apoptosis and senescence. Intriguingly, we find here that this mutant uncouples the p53 senescence and apoptotic responses, thereby providing new insight into the mode of p53 action in tumor suppression. retention of the p53 DNA binding domain, but bereft of other amino-terminal functional motifs. We generated a targeting vector carrying this p53 VP16 mutant and a transcriptional stop cassette flanked by LoxP recombination sites (lox-stop-lox, LSL) upstream of the p53 coding region to silence the allele until Cre recombinase introduction (Fig. 1A) . Because this chimera cannot bind the E3 ubiquitin ligase Mdm2, which normally interacts with p53's amino terminus and plays a critical role in p53 down-regulation, inclusion of the stop element should prevent embryonic lethality associated with unrestrained p53 in the developing embryo (17, 18) . The targeting vector was introduced into ES cells, and correctly targeted clones were used to generate mice (Fig. 1B) .
To analyze this mutant, we used mouse embryo fibroblasts (MEFs), a readily manipulable cell type in which p53 effector functions are well characterized. After generation of homozygous LSL-p53 VP16 and control LSL-p53 wt (19) , we infected cells with either adenoviruses expressing Cre (Ad-Cre) to excise the stop element, or as a control, empty adenoviruses, leaving the cells effectively p53 null. Greater than 95% of cells expressed detectable p53 protein, as determined by immunostaining of Ad-Cre-infected MEFs ( Fig. 1C; data not shown) . To compare levels of wild-type p53 and p53 wt proteins, we performed Western blotting. Endogenous p53 is found at low levels in the cell because of proteasomal degradation mediated by Mdm2, and is stabilized in response to cellular stresses such as DNA damage (20, 21) . Accordingly, in homozygous LSL-p53 wt MEFs, p53 protein was absent in Ad-empty-infected cells and nearly undetectable on Ad-Cre infection, but highly up-regulated in cells infected with Ad-Cre and treated with the DNA-damaging agent doxorubicin (Fig. 1D) . As expected for a p53 mutant unable to bind Mdm2, the p53 VP16 mutant was stabilized in Ad-Creinfected MEFs even in the absence of DNA damage, accumulating to levels similar to those of wild-type p53 after DNA damage (Fig. 1D ). These studies establish this system as an effective one in which to compare the function of the p53 VP16 protein with wild-type p53.
To examine the potential of the p53 VP16 chimera to activate p53 target gene expression, we evaluated its ability to both bind DNA and induce a panel of canonical p53 target genes. In electromobility shift assays, p53 VP16 retained the ability to bind in a sequence-specific manner to p53 response elements from the p21 and Perp regulatory regions ( Fig. 2A ; data not shown). To evaluate the transactivation capacity of this mutant, we examined endogenous target gene expression by Northern blot analysis. Whereas MEFs expressing wild-type p53 displayed modest induction of genes such as p21, Noxa, and Perp in a basal state and significant up-regulation in response to DNA damage, MEFs expressing p53 VP16 exhibited strong induction of a broad range of p53-regulated genes, including genes involved in cell cycle arrest, negative feedback regulation, and apoptosis, even in the absence of DNA damage (Fig. 2B) . Thus, this mutant can bind to various p53-responsive elements and efficiently transactivate endogenous target genes, validating its competency as a transactivator. Furthermore, these data indicate that the specificity of p53 activation of its target genes relies on the DNA binding domain rather than the transactivation domain. 
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Free probe Ad-Cre Ad-empty dox - To assess the biological capabilities of the p53 VP16 mutant, we initially examined its ability to induce apoptosis, an activity of p53 essential for its tumor suppressor function in vivo (22, 23) . Although untransformed MEFs are typically refractory to apoptosis, we hypothesized that because the p53 VP16 mutant can potently transactivate a variety of proapoptotic p53 target genes in the absence of a cellular stress, it may elicit an apoptotic response without a sensitizing stress signal. However, we found that p53 VP16 -expressing cells displayed minimal cell death, suggesting that robust transactivation of proapoptotic p53 target genes, such as Bax, Perp, and Noxa, is insufficient to induce MEFs to undergo apoptosis (Fig. 3A) .
The inability of p53 VP16 to display apoptotic activity may reflect a requirement for a collateral signal to sensitize MEFs to undergo apoptosis. Specifically, MEFs either treated with UV light or expressing oncoproteins, such as c-Myc or adenoviral E1A, and exposed to various stresses are highly sensitized to undergo p53-dependent apoptosis (24) (25) (26) . We found that, although MEFs expressing wild-type p53 exhibited significant apoptosis in response to UVC, MEFs expressing p53 VP16 displayed levels of cell death equivalent to those lacking p53 (Fig.  3B) . Thus, even in the context of DNA damage signaling, the p53 VP16 mutant is incapable of inducing apoptosis. We next evaluated the ability of p53 VP16 to induce apoptosis in c-Mycexpressing MEFs treated with doxorubicin. Myc-MEFs expressing wild-type p53 underwent efficient cell death, whereas those expressing the p53 VP16 mutant were unable to undergo apoptosis (Fig. 3C) . Thus, despite being capable of potently up-regulating proapoptotic p53 target genes, the p53 VP16 mutant is unable to induce apoptosis in a variety of contexts, suggesting that transactivation capacity is not sufficient for p53-mediated apoptosis in MEFs, and that other functions may be critical for p53 to trigger cell death.
Another critical means by which p53 limits the expansion of neoplastic cells is through induction of a permanent cell cycle arrest or cellular senescence (27) (28) (29) . We examined the ability of p53 VP16 to elicit a growth arrest in response to doxorubicin by using BrdU incorporation assays to assess S-phase entry. MEFs expressing wild-type p53, but not treated with DNA damage, showed an Ϸ2-fold decrease in the BrdU-labeling index relative to cells lacking p53 (Fig. 4A) . On DNA damage treatment, cells expressing wild-type p53 halted cell cycle progression, as noted by the virtual absence of BrdU-positive cells. Interestingly, p53 VP16 -expressing MEFs exhibited a dramatic cell cycle arrest even in the absence of DNA damage. Thus, this transactivation mutant, although unable to induce apoptosis, can enforce a potent cell cycle arrest. That this arrest is specific and relates to sequence-specific DNA binding was verified by using a DNA binding domain mutant of p53 (R248W), which acts as a dominant negative to inhibit wild-type p53 binding to DNA (30) . When the p53 R248W mutant was introduced into p53 VP16 -expressing MEFs, the ability of p53 VP16 to arrest cells was abrogated, indicating that p53 VP16 triggers arrest through DNA binding (Fig. 5) .
We demonstrated that this arrest reflects a senescence response, because p53 VP16 -expressing MEFs displayed a prolonged growth arrest and exhibited robust staining for senescenceassociated ␤-galactosidase (SA-␤gal; Fig. 4 B and C) . Notably, this response was rapid, manifested within 4 days, and occurred in the absence of DNA damage or oncogenic signals. Additionally, p53 VP16 -expressing MEFs displayed augmented promyelocytic leukemia (Pml) levels, another hallmark of senescence (31), compared with p53-deficient MEFs (Fig. 4D) . Thus, in the absence of exogenous stress, the p53 VP16 mutant is competent to elicit a potent cell cycle arrest recapitulating various features of senescence. These findings highlight the importance of transactivation of target genes, rather than other amino-terminal domain activities, for the p53 senescence program.
Because the p53 VP16 mutant induced such a vigorous growth arrest in untransformed MEFs, we evaluated its ability to trigger senescence in MEFs expressing oncogenes to determine whether a p53-mediated growth arrest is capable of preventing the expansion of cells with tumorigenic potential. We first found that Myc-MEFs expressing the p53 VP16 mutant did not proliferate, and once again stained positive for SA-␤gal, in contrast to Myc-MEFs expressing wild-type p53, indicating that even in the context of a strong oncogenic signal, potent transactivation by p53 engenders a senescence response (Fig. 6A) . We then examined the activity of p53 VP16 in the context of another oncoprotein, adenoviral E1A, which disrupts the G 1 cell cycle checkpoint by inhibiting the Rb family of proteins (32) . Interestingly, on measuring S-phase entry, we found that E1A-MEFs expressing p53 VP16 exhibited BrdU positivity to levels commensurate with those seen in cells expressing wild-type p53, and failed to stain positive for SA-␤gal after 4-8 days in culture (Fig. 6 B and C; data not shown). Thus, the ability of this p53 VP16 chimera to trigger cellular senescence strictly depends on the integrity of Rb family proteins to impose a cell cycle checkpoint.
It remained possible that the apoptotic defect we detected in cells expressing p53 VP16 was not due to inherent deficiencies in this protein's ability to induce cell death, but instead, was the result of the rapid growth arrest induced by p53 VP16 inappropriately driving the cell fate decision away from the apoptotic program. We therefore evaluated the ability of p53 VP16 to induce apoptosis in the context of E1A expression, a setting in which p53 VP16 cannot elicit growth arrest. On doxorubicin treatment, we found that E1A-p53 VP16 -MEFs still displayed a marked apoptotic defect, with levels of cell death significantly lower than those seen in E1A-MEFs expressing wild-type p53 (Fig. 6D) . Importantly, the p53 VP16 protein retained its ability to transactivate p53 target genes in these E1A-expressing MEFs (Fig. 6E) . Thus, even in fibroblasts competent to proliferate, p53 VP16 cannot induce apoptosis.
To examine the activity of p53 VP16 in an in vivo setting, we assessed the consequences of p53 VP16 expression during development. Mdm2Ϫ/Ϫ mice have been shown to display early embryonic lethality because of the failure to down-regulate p53 (18) . Given that p53 VP16 cannot bind Mdm2 and can induce senescence in some settings, its expression during development may induce embryonic lethality similar to that seen in mice MEFs were infected with retroviruses expressing the p53 R248W mutant (dominant negative or DNp53), and 4 days later were infected with adeno-Cre or Adeno-empty for 24 h. Cells were then pulsed with BrdU for 4 h, fixed, and stained for BrdU incorporation and p53 expression. As seen in the graph on the left, cells expressing both p53 R248W and p53 VP16 incorporated high levels of BrdU, similar to the levels seen in cells expressing no p53 protein (LSL-VP16 ϩ empty) or only p53 R248W (LSL-VP16 ϩ empty ϩ DNp53), suggesting that no cell cycle arrest occurred. In contrast, cells expressing only p53 VP16 (LSL-VP16 ϩ Cre) showed very minimal BrdU incorporation, indicative of a strong cell cycle arrest. Representative images of the data graphed on the left are shown on the right. The bottom two rows of images use an antibody raised against the VP16 transactivation domain to show that the p53 VP16 protein is expressed in cells also expressing the p53 R248W mutant. VP16/ϩ adults with a deleted stop cassette were observed (Table 1 , P Ͻ 0.0002). In conjunction with the lack of postnatal lethality observed in the progeny from these crosses, these data suggest that expression of p53 VP16 during development results in embryonic lethality. This finding highlights the functional potential of this mutant in vivo, despite its inability to trigger apoptosis, and suggests the possibility that it may have activity in tumor suppression.
The generation and analysis of p53 functional mutants, in which non-tumor-derived mutant versions of p53 are queried for their biological activities, is critical for better understanding the mechanism of p53 action. Here, we have described a p53 knockin mouse strain in which we have manipulated the amino terminus of p53 to dissect the relative roles of transactivation and other activities for p53 function. Our findings demonstrate that, despite being competent to transactivate both critical arrest and apoptotic target genes, the p53 VP16 chimera shows dramatic selectivity in p53 effector function in fibroblasts, displaying a profound apoptotic defect in a variety of settings, but retaining the ability to trigger a potent cellular senescence response. These findings suggest that, of the various amino-terminal activities, transcriptional activation is insufficient for p53's ability to direct an apoptotic response but suffices for the engagement of the senescence response. The lack of apoptotic potential of p53 VP16 is surprising considering its capacity to induce robust expression of multiple proapoptotic p53 targets. The inability of p53 to induce apoptosis in specific contexts has been attributed to the insufficient expression of p53 target genes involved in apoptosis (3) . Specifically, proteins involved in biasing cells toward apoptosis, such as ASPP and JMY, do so by augmenting p53 target gene expression above a critical threshold required to provoke apoptosis (33, 34) . That p53 VP16 can direct high-level target gene expression yet cannot trigger apoptosis suggests the absence in this chimera of some other critical functional domain required for apoptosis. A host of distinct proteins can interact with the p53 amino terminus, and substitution of this region with the VP16 activation domain may disrupt interactions with other proteins important for the ability of p53 to induce apoptosis. For example, p53 action as a transrepressor may be critical for its ability to induce apoptosis. A range of genes is repressed in cells expressing wild-type p53 relative to cells lacking p53 (35) , and the contribution of transcriptional repression to p53 function remains poorly defined. Because p53 represses transcription through interactions of residues 61-75 in the polyproline domain with mSin3a, p53 VP16 has likely lost this ability (12) . Alternatively, p53 interacts with Bcl-2 family members through the polyproline domain (10, 15) , and it is possible that these interactions are disrupted in p53 VP16 -expressing cells, thereby contributing to the apoptosis deficit. An additional possibility is that a subset of unknown p53 targets involved in apoptosis are activated through a different mechanism from canonical targets, and the failure of p53 VP16 to induce apoptosis relates to an inability to recruit specific cofactors important for the transactivation of these genes. Thus, other amino-terminal activitiessuch as transcriptional repression, mitochondrial action, or transactivation through a new mechanism-may be key for generating an apoptotic response. These findings suggest further a possible rationale for why certain cell types undergo apoptosis instead of cell cycle arrest in response to p53 activation, because the apoptotic cell fate could be dictated by the engagement of these alternate amino-terminal p53 activities in select contexts.
In contrast to the apoptotic deficit, p53 VP16 elicits a rapid growth arrest with characteristics of cellular senescence. That this phenotype occurs in p53 VP16 -expressing cells in the absence of any exogenous stimulus, such as oncogene activation, oxidative stress, or acute DNA damage, indicates that the senescence response is strictly dependent on the inherent activity of p53 VP16 . Whereas the contribution of the p53-inducible genes Pml and Pai-1 to the senescence program has been suggested (36, 37) , a definitive role of other functions has been unclear. Our observations emphasize the pivotal role for target gene activation, rather than other amino-terminal activities of p53, for engaging a senescence response. Further analysis of this mutant, selectively disrupted for apoptosis but not senescence, will provide a broader understanding of the downstream functions of p53 important for tumor suppression.
Materials and Methods
Generation of LSL-p53 VP16 Mice. We constructed a targeting vector by using a genomic fragment of Trp-53 comprising intron 1-exon 6. The transcriptional stop cassette (19) , including four tandem poly(A) sequences and a PGKpuromycin selection marker flanked by loxP sites, was inserted into the second XhoI site in Trp-53 intron 1. The VP16 activation domain-encoding sequences were generated by PCR by using the plasmid pAT-VP16-p53 (38) as a template, and replaced sequences between the NcoI sites in exons 2 and 4 of the Trp-53 genomic region. An HSV-thymidine kinase negative selection cassette was introduced downstream of exon 6. The targeting construct was introduced into J1 129Sv/J ES cells, which were subjected to puromycin and gancyclovir selection. We screened for correctly targeted ES cell clones performing Southern blot analysis as described in ref. 19 with 5Ј and 3Ј external probes to detect the stop element and the VP16 activation domain. We injected two independent, correctly targeted ES cell clones into blastocysts to generate mice and characterized both lines in our experiments. Genotyping was performed as described in Fig. 1 . All work was performed in accordance with the Stanford University Administrative Panel for Laboratory Animal Care.
Cell Culture and Viral Infections. MEFs were derived from E13.5 embryos on a pure 129Sv/J or mixed 129Sv/J-C57BL/6 background as described in ref. 19 and were used by passage 6. Infections with empty adenovirus and adenovirus-Cre (University of Iowa GTVR) were performed as described in ref. 19 . Retroviral infections were performed as described in ref. 19 , with the following modifications: for experiments involving MEFs expressing the E1A oncoprotein and the CreER fusion protein, E1A was introduced first, cells were selected for 2 days in hygromycin (200 g/ml), and then cells were infected with CreER retroviruses, followed by selection in both hygromycin (200 g/ml) and geneticin (500 g/ml) for 4 days. The CreER fusion protein was activated by the administration of 1 M 4-hydroxytamoxifen (Sigma).
Gene and Protein Expression Analysis. Electromobility shift assays (EMSAs), Northern blotting, Western blotting, and immunofluorescence were performed as described in ref. 19 . For Western blotting, we used antibodies 
